This video examines results of the CHARTA trial, which tested first-line FOLFOX plus bevacizumab with or without irinotecan in patients with advanced colorectal cancer.
Hans-Joachim Schmoll, MD, PhD
Advertisement
Articles by Hans-Joachim Schmoll, MD, PhD
Advertisement
Latest Updated Articles
CHARTA Shows Survival Benefit of Four-Drug Regimen for Advanced CRCPublished: January 21st 2017 | Updated:
Advertisement
Advertisement
Trending on CancerNetwork
1
Casdatifan Monotherapy Achieves Clinical Activity in Late-Line Kidney Cancer
2
Dato-DXd Improves Survival in Recurrent Inoperable/Metastatic TNBC
3
How Will RLTs Be Integrated Into the Prostate Cancer Treatment Paradigm?
4
Intravesical Mitomycin Produces Enduring Efficacy Across NMIBC Trials
5
